Annalisa Rubino is Director of Risk Management Epidemiology with OXON Epidemiology. She is a Pharmacoepidemiologist with extensive research experience in drug development in academia and industry. She has worked in consultancy for the pharmaceutical industry in therapeutic risk management and drug safety and has published more than 50 papers. Before joining OXON she was a Scientific Officer at EMA where she focused on risk minimisation in the context of the 2010 EU Pharmacovigilance legislation